Ten-Year Outcome of Islet Alone or Islet After Kidney Transplantation in Type 1 Diabetes: A Prospective Parallel-Arm Cohort Study (original) (raw)

Skip Nav Destination

Clinical Care/Education/Nutrition/Psychosocial Research| October 10 2019

Marie-Christine Vantyghem

;

Marie-Christine Vantyghem

1University of Lille, U1190-EGID, Lille, France

2Department of Endocrinology, Diabetology, and Metabolism, Centre Hospitalier Universitaire de Lille, Lille, France

3Inserm, U1190, Lille, France

Search for other works by this author on:

Mikael Chetboun;

1University of Lille, U1190-EGID, Lille, France

3Inserm, U1190, Lille, France

4Department of General and Endocrine Surgery, Centre Hospitalier Universitaire de Lille, Lille, France

Search for other works by this author on:

Valéry Gmyr;

1University of Lille, U1190-EGID, Lille, France

3Inserm, U1190, Lille, France

Search for other works by this author on:

Arnaud Jannin;

2Department of Endocrinology, Diabetology, and Metabolism, Centre Hospitalier Universitaire de Lille, Lille, France

Search for other works by this author on:

Stéphanie Espiard;

2Department of Endocrinology, Diabetology, and Metabolism, Centre Hospitalier Universitaire de Lille, Lille, France

Search for other works by this author on:

Kristell Le Mapihan;

2Department of Endocrinology, Diabetology, and Metabolism, Centre Hospitalier Universitaire de Lille, Lille, France

Search for other works by this author on:

Violeta Raverdy;

1University of Lille, U1190-EGID, Lille, France

3Inserm, U1190, Lille, France

Search for other works by this author on:

Nathalie Delalleau;

1University of Lille, U1190-EGID, Lille, France

3Inserm, U1190, Lille, France

Search for other works by this author on:

François Machuron;

5Department of Methodology, Biostatistics, and Data Management, Centre Hospitalier Universitaire de Lille, Lille, France

Search for other works by this author on:

Thomas Hubert;

1University of Lille, U1190-EGID, Lille, France

3Inserm, U1190, Lille, France

Search for other works by this author on:

Marie Frimat;

6Department of Nephrology, Centre Hospitalier Universitaire de Lille, Lille, France

Search for other works by this author on:

Eric Van Belle;

7Department of Cardiology, Centre Hospitalier Universitaire de Lille, Lille, France

Search for other works by this author on:

Marc Hazzan;

6Department of Nephrology, Centre Hospitalier Universitaire de Lille, Lille, France

Search for other works by this author on:

Pascal Pigny;

8Department of Biochemistry and Hormonology, Centre Hospitalier Universitaire de Lille, Lille, France

Search for other works by this author on:

Christian Noel;

6Department of Nephrology, Centre Hospitalier Universitaire de Lille, Lille, France

Search for other works by this author on:

Robert Caiazzo;

1University of Lille, U1190-EGID, Lille, France

3Inserm, U1190, Lille, France

4Department of General and Endocrine Surgery, Centre Hospitalier Universitaire de Lille, Lille, France

Search for other works by this author on:

Julie Kerr-Conte;

1University of Lille, U1190-EGID, Lille, France

3Inserm, U1190, Lille, France

Search for other works by this author on:

François Pattou;

1University of Lille, U1190-EGID, Lille, France

3Inserm, U1190, Lille, France

4Department of General and Endocrine Surgery, Centre Hospitalier Universitaire de Lille, Lille, France

Search for other works by this author on:

Crossmark: Check for Updates

*

A complete list of the members of the working groups Diaménord, G4, and Platform of Biotherapy appears in the Supplementary Data online.

Diabetes Care 2019;42(11):2042–2049

Citation

Marie-Christine Vantyghem, Mikael Chetboun, Valéry Gmyr, Arnaud Jannin, Stéphanie Espiard, Kristell Le Mapihan, Violeta Raverdy, Nathalie Delalleau, François Machuron, Thomas Hubert, Marie Frimat, Eric Van Belle, Marc Hazzan, Pascal Pigny, Christian Noel, Robert Caiazzo, Julie Kerr-Conte, François Pattou, on behalf of the working groups Diaménord, G4, and Platform of Biotherapy; Ten-Year Outcome of Islet Alone or Islet After Kidney Transplantation in Type 1 Diabetes: A Prospective Parallel-Arm Cohort Study. _Diabetes Care 1 November 2019; 42 (11): 2042–2049. https://doi.org/10.2337/dc19-0401

Download citation file:

OBJECTIVE

The long-term outcome of allogenic islet transplantation is unknown. The aim of this study was to evaluate the 10-year outcome of islet transplantation in patients with type 1 diabetes and hypoglycemia unawareness and/or a functioning kidney graft.

RESEARCH DESIGN AND METHODS

We enrolled in this prospective parallel-arm cohort study 28 subjects with type 1 diabetes who received islet transplantation either alone (ITA) or after a kidney graft (IAK). Islet transplantation consisted of two or three intraportal infusions of allogenic islets administered within (median [interquartile range]) 68 days (43–92). Immunosuppression was induced with interleukin-2 receptor antibodies and maintained with sirolimus and tacrolimus. The primary outcome was insulin independence with A1C ≤6.5% (48 mmol/mol). Secondary outcomes were patient and graft survival, severe hypoglycemic events (SHEs), metabolic control, and renal function.

RESULTS

The primary outcome was met by (Kaplan-Meier estimates [95% CI]) 39% (22–57) and 28% (13–45) of patients 5 and 10 years after islet transplantation, respectively. Graft function persisted in 82% (62–92) and 78% (57–89) of case subjects after 5 and 10 years, respectively, and was associated with improved glucose control, reduced need for exogenous insulin, and a marked decrease of SHEs. ITA and IAK had similar outcomes. Primary graft function, evaluated 1 month after the last islet infusion, was significantly associated with the duration of graft function and insulin independence.

CONCLUSIONS

Islet transplantation with the Edmonton protocol can provide 10-year markedly improved metabolic control without SHEs in three-quarters of patients with type 1 diabetes, kidney transplanted or not.

Clinical trial reg. nos. NCT01123187 and NCT00446264, clinicaltrials.gov

M.-C.V. and M.C. contributed equally to this work.

© 2019 by the American Diabetes Association.

2019

You do not currently have access to this content.

Sign in

Pay-Per-View Access

$40.00

3,965 Views

79 Web of Science

Email alerts